Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Biogen Inc. before investing.

In this article, we go over a few key elements for understanding Biogen Inc.’s stock price such as:

• Biogen Inc.’s current stock price and volume
• Why Biogen Inc.’s stock price changed recently
• Upgrades and downgrades for BIIB from analysts
• BIIB’s stock price momentum as measured by its relative strength

About Biogen Inc. (BIIB)

Before we jump into Biogen Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer’s disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Biogen Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Biogen Inc..

Biogen Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Biogen Inc.’s stock price was $202.950.

Biogen Inc. is down 2.4% from its previous closing price of $207.930.

During the last market session, Biogen Inc.’s stock traded between $202.570 and $208.050. Currently, there are approximately 147.70 million shares outstanding for Biogen Inc..

Biogen Inc.’s price-earnings (P/E) ratio is currently at 36.9, which is high compared to the Biotechnology industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Biogen Inc. Stock Price History

Biogen Inc.’s (BIIB) price is currently down 6.07% so far this month.

During the month of July, Biogen Inc.’s stock price has reached a high of $219.010 and a low of $186.025.

Over the last year, Biogen Inc. has hit prices as high as $219.720 and as low as $124.556. Year to date, Biogen Inc.’s stock is up 15.32%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Biogen Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 0 analysts who downgraded Biogen Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Biogen Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Biogen Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Biogen Inc.’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Biogen Inc. (BIIB) by visiting AAII Stock Evaluator.

Relative Price Strength of Biogen Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Biogen Inc. has a weighted four-quarter relative price strength of 8.47%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how Biogen Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Biogen Inc. Stock Price: Bottom Line

As of July 31, 2026, Biogen Inc.’s stock price is $202.950, which is down 2.4% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Biogen Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.